Feedback
Breast Cancer Biomarkers Profile, Quantitative by PCR (INACTIVE as of 07/02/12)
2005451
Ordering Recommendation
Mnemonic
BRST MARK
Methodology
Quantitative Reverse Transcription Polymerase Chain Reaction
Performed
Varies
Reported
12-14 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Tumor tissue. 
Specimen Preparation
Formalin fix (10% neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. 
Storage/Transport Temperature
Room temperature or refrigerated. Ship in cooled container during summer months. 
Unacceptable Conditions
Specimens with less than 75 percent tumor. Frozen specimens. Specimens fixed/processed in alternative fixatives (alcohol, Prefer®) or heavy metal fixatives (B-4 or B-5). Decalcified specimens. 
Remarks
Surgical report requested. Direct punches may be required to complete testing. Client will be contacted for permission if a direct punch is required. Tissue block will be returned after testing. 
Stability
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Refer to report.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Using PCR this assay will report qualitative and quantitative values for ESR1 (ER), PGR (PR), ERBB2 (HER2) and Proliferation. Additional information and supporting literature regarding biomarker quantitative measurements and breast cancer subtyping is available at http://www.aruplab.com/PAM50.
CPT Code(s)
83907 Lysis; 83891 Isolation; 83902 Reverse transcription; 83898 x18 Amplification; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
Components
Component Test Code*Component Chart NameLOINC
2002148Block ID57723-9
2005452Breast Cancer Biomarkers Information
2005614Breast Biomarker - ERBB2 Qualitative
2005615Breast Biomarker - ERBB2 Quantitative
2005616Breast Biomarker - Proliferation, Qual
2005617Breast Biomarker - Proliferation, Quant
2005618EER Breast Cancer Biomarkers
2005619Breast Biomarker - ESR1 Qualitative
2005620Breast Biomarker - PGR Qualitative
2005621Breast Biomarker - ESR1 Quantitative
2005622Breast Biomarker - PGR Quantitative
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases